Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Nov 13 2025

0mins

MNPR-6.38%

Should l Buy MNPR?

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MNPR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MNPR

Wall Street analysts forecast MNPR stock price to rise

11 Analyst Rating

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 59.240

Low

95.00

Averages

112.91

High

130.00

Current: 59.240

Low

95.00

Averages

112.91

High

130.00

Morgan Stanley

Maxwell Skor

Overweight

initiated

$115

2026-01-09

Reason

Morgan Stanley

Maxwell Skor

Price Target

$115

AI Analysis

2026-01-09

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics with an Overweight rating and $115 price target. The firm says ALXN1840 demonstrated "meaningful" copper mobilization and neurological benefit in a Phase 3 study as a "differentiated therapy" for Wilson's disease with a once-daily profile. The analyst sees an "encouraging set-up" for the shares.

Raymond James

Christopher Raymond

Strong Buy -> Outperform

downgrade

$142 -> $123

2025-11-14

Reason

Raymond James

Christopher Raymond

Price Target

$142 -> $123

2025-11-14

downgrade

Strong Buy -> Outperform

Reason

Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm's key opinion leader feedback indicates a "heavier commercial" lift than first imagined for Monopar in Wilson disease. A " higher risk premium to our estimates is warranted here," the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MNPR

Unlock Now

About MNPR

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings

Jan 09 2026CNBC

Price Target Adjustment: Goldman Sachs has cut its price target for Netflix from $130 to $112, reflecting a cautious outlook ahead of the upcoming earnings report, which is expected to show solid performance by the end of 2025 as management executes its core strategic focus.
Content Strategy: Goldman emphasizes that Netflix will continue to rely on original and returning original content to drive user engagement and growth, a strategy that may impact user retention and market share in the competitive streaming landscape.
Market Expectations: While Goldman maintains a neutral rating on Netflix, the market's reaction to the forthcoming earnings report could lead to stock price volatility, particularly given the uncertainties in the macroeconomic environment.
Competitive Pressure: Netflix faces competitive pressures from other streaming platforms, especially regarding content richness and user experience, which could affect its growth potential moving forward.

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

Dec 31 2025Benzinga

Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.

Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925

Dec 29 2025NASDAQ.COM

Insider Purchase: Monopar Therapeutics CFO Quan Anh Vu purchased 1,500 shares of MNPR at $69.95 each on Friday, totaling an investment of $104,925, indicating confidence in the company's future prospects.
Market Reaction: Despite Vu's purchase signaling optimism about the company's outlook, MNPR's stock fell approximately 1.1% on Monday, reflecting market caution regarding the company's current situation.
Purchase Frequency: This marks Vu's first stock purchase in the past 12 months, potentially indicating a reassessment of the company's value or expectations for future performance.
Investor Confidence: Insider buying is generally viewed as a positive signal for the company's future, which may bolster confidence among other investors, even though the stock's short-term performance remains weak.

Home Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday

Nov 14 2025Benzinga

Analyst Downgrades: Several top Wall Street analysts have downgraded their ratings on various companies, including Gambling.com Group Ltd, Ardent Health Inc, Home Depot Inc, Flowserve Corp, and Monopar Therapeutics Inc.
Gambling.com Group Ltd: BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral, with shares closing at $5.25.
Ardent Health Inc: Morgan Stanley's Craig Hettenbach downgraded the rating from Overweight to Equal-Weight, reducing the price target from $22 to $12, with shares closing at $9.30.
Home Depot Inc: Stifel analyst W. Andrew Carter downgraded the stock from Buy to Hold, lowering the price target from $440 to $370, with shares closing at $368.07.